• Medical_Professionals
• Medical_students
• Nurses

SMi Group are proud to present the 2nd Annual Ophthalmic Drugs Conference on 26th - 27th November 2018, London, United Kingdom.

As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of this market. In fact, the global ophthalmic drug market is projected to reach £30 billion by 2023, growing at a CAGR of 5.3% from 2017 to 2023 (Via *Allied Market Research)

Join industry experts from Roche, Santen, Aerie Pharmaceuticals, MHRA, Nightstar Therapeutics and more to discuss and analyze the latest advancements and challenges within ophthalmic drug development. Network with industry professionals, explore novel approaches to treatment of ocular diseases, gain insight into ongoing clinical trials, discover how technology is revolutionising pharmaceutical R&D, and get invaluable advice on how to enhance development and overcome challenges within the industry.

Developing on last years success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs. Join us to network with ophthalmic experts from top pharmaceutical companies.

Gain insight into...

The discovery of the first FDA-approved ROCK inhibitor for the treatment of glaucoma

Non-invasive drug delivery technology for anterior segment ocular disease

Novel treatments for Glaucoma / Retinoprotection

Advantages of site-specific biologics for ocular diseases

Current neuroprotective agents under investigation for the treatment of ocular disease.

Exploring artificial intelligence in drug discovery

How to keep up with the ever changing regulatory environment, and to overcome challenges in regulation.

Gene delivery and gene editing in the retina

GBP

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

COPTHORNE TARA HOTEL

Scarsdale Place, Kensington, London, United Kingdom

Submission Info

+44 (0)20 7827 6000

EVENTS@SMI-ONLINE.CO.UK

EXPERIMENTICA LTD.

Sponsors and Exhibitors

http://www.experimentica.com 

Experimentica Ltd. is a Finland-based contract research organisation (CRO) dedicated to developing and offering preclinical ocular models and services to clients in the pharmaceutical, biotech and academic sectors. Founded in 2013 Experimentica Ltd. offers exclusively in-house expertise and an industry-leading portfolio of functional assays and in vivo imaging for preclinical ocular models. The mission of Experimentica Ltd. is to bridge a gap between the development of novel ocular models and their use in developing clinical applications.

 sponsor image

NEMERA

Sponsors and Exhibitors

http://www.nemera.net 

Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generics industries. Nemera’s services and products cover several key delivery routes: Ophthalmic, Parenteral, Nasal, Buccal, Auricular, Pulmonary, Dermal and Transdermal. Nemera always puts patients first, providing the most comprehensive range of devices in the industry, including off-the-shelf innovative systems, customized design development and contract manufacturing. In particular, we provide millions of multidose eye droppers for preservative-free formulations.

EVENTS@SMI-ONLINE.CO.UK